Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept study of elezanumab in acute ischemic stroke
2019-003753-29Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Elezanumab arm with Placebo arm (2 arms). Primary endpoint: NIHSS total score during the Treatment Period. Started May 2020; status: active.
02
Drugs
elezanumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2019-003753-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003753-29.